| Literature DB >> 29234056 |
Friederike Flachsbart1, Janina Dose1, Liljana Gentschew1, Claudia Geismann2, Amke Caliebe3, Carolin Knecht3, Marianne Nygaard4, Nandini Badarinarayan1, Abdou ElSharawy1,5, Sandra May1, Anne Luzius1, Guillermo G Torres1, Marlene Jentzsch1, Michael Forster1, Robert Häsler1, Kathrin Pallauf6, Wolfgang Lieb7, Céline Derbois8, Pilar Galan9, Dmitriy Drichel10, Alexander Arlt2, Andreas Till1,11, Ben Krause-Kyora1,12, Gerald Rimbach6, Hélène Blanché13, Jean-François Deleuze8,13, Lene Christiansen4, Kaare Christensen4,14, Michael Nothnagel10, Philip Rosenstiel1, Stefan Schreiber1,2, Andre Franke1, Susanne Sebens15, Almut Nebel16.
Abstract
FOXO3 is consistently annotated as a human longevity gene. However, functional variants and underlying mechanisms for the association remain unknown. Here, we perform resequencing of the FOXO3 locus and single-nucleotide variant (SNV) genotyping in three European populations. We find two FOXO3 SNVs, rs12206094 and rs4946935, to be most significantly associated with longevity and further characterize them functionally. We experimentally validate the in silico predicted allele-dependent binding of transcription factors (CTCF, SRF) to the SNVs. Specifically, in luciferase reporter assays, the longevity alleles of both variants show considerable enhancer activities that are reversed by IGF-1 treatment. An eQTL database search reveals that the alleles are also associated with higher FOXO3 mRNA expression in various human tissues, which is in line with observations in long-lived model organisms. In summary, we present experimental evidence for a functional link between common intronic variants in FOXO3 and human longevity.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29234056 PMCID: PMC5727304 DOI: 10.1038/s41467-017-02183-y
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Association statistics for the FOXO3 SNVs rs4946935 and rs12206094 in the whole German study population and centenarian subpopulation
| SNV | Study population | MAFa LLI | MAFa Controls |
| ORc | 95% C.I.d |
|---|---|---|---|---|---|---|
|
| ||||||
| rs4946935 | ||||||
| Total | 0.349 | 0.304 | 0.003 | 1.228 | 1.072–1.406 | |
| Female | 0.350 | 0.313 | 0.037 | 1.181 | 1.010–1.381 | |
| Male | 0.347 | 0.278 | 0.022 | 1.375 | 1.046–1.808 | |
| rs12206094 | ||||||
| Total | 0.325 | 0.287 | 0.010 | 1.196 | 1.044–1.369 | |
| Female | 0.322 | 0.291 | 0.068 | 1.157 | 0.989–1.353 | |
| Male | 0.333 | 0.275 | 0.045 | 1.318 | 1.006–1.726 | |
|
| ||||||
| rs4946935 | ||||||
| Total | 0.370 | 0.304 | 0.0003 | 1.345 | 1.147–1.577 | |
| Female | 0.372 | 0.313 | 0.004 | 1.303 | 1.088–1.559 | |
| Male | 0.360 | 0.278 | 0.032 | 1.458 | 1.032–2.060 | |
| rs12206094 | ||||||
| Total | 0.345 | 0.287 | 0.001 | 1.306 | 1.116–1.529 | |
| Female | 0.342 | 0.291 | 0.011 | 1.261 | 1.055–1.508 | |
| Male | 0.357 | 0.275 | 0.024 | 1.469 | 1.052–2.050 | |
Listed are allele frequencies, allelic P values, odds ratios, and the 95% confidence intervals for the whole study population and centenarian subpopulation (1109 LLI ≥ 95 years including 594 centenarians, 918 younger controls (age range: 60–75 years)). The statistics are listed for all individuals of the study populations as well as for males and females separately (males: 275 LLI ≥ 95 years including 119 centenarians, 237 younger controls; females: 834 LLI ≥ 95 years including 475 centenarians, 681 younger controls)
a Minor allele frequency, MAF; the definition of the minor allele is based on controls; minor alleles are A for rs4946935 and T for rs12206094
b Allelic P values, PCCA; calculated with chi-squared test with one degree of freedom
c Odds ratio for longevity, OR; based on the minor allele in controls
d 95% confidence interval, 95% C.I.; C.I. for the odds ratio
Fig. 1Association plot shows all 205 SNVs tested in the FOXO3 gene region on chromosome 6 (hg18). The two SNVs with the best P values are indicated (red circles). The four exons are shown in the gene model. Number of individuals: 594 German long-lived individuals (≥100 years) and 918 controls (60–75 years). PCCA, allelic P values, determined in a case–control association study by chi-squared test with one degree of freedom; −log10PCCA, negative decadic logarithm of allelic P values
Odds ratios of the combined genotypes of rs12206094 and rs4946935
| rs12206094 | ||||
|---|---|---|---|---|
| CC | CT | TT | ||
| rs4946935 | GG | 1, | 1.81, | 3.27, |
| AG | 1.81, | 1.92 (3.28), | 2.04 (5.92), | |
| AA | 3.29, | 2.05 (5.95), | 1.28 (10.76), | |
Given are the odds ratios (ORs) for the allelic interaction model (multiplicative OR scale). In brackets are the theoretic combined ORs if no interaction were present (given the same single SNV ORs). The underlying population is the German longevity sample with 594 centenarians and 918 younger controls. n = number of individuals
Association statistics for the SNVs rs4946935 and rs12206094 in the French and Danish replication cohorts, respectively
| SNV | Study population | MAFa LLI | MAFa Controls |
| ORc | 95% C.I.d |
|---|---|---|---|---|---|---|
|
| ||||||
| French | Total | 0.324 | 0.297 | 0.022 | 1.136 | 1.018–1.268 |
| Female | 0.318 | 0.294 | 0.094 | 1.118 | 0.981–1.274 | |
| Male | 0.355 | 0.302 | 0.032 | 1.273 | 1.020–1.589 | |
| Danish | Total | 0.304 | 0.278 | 0.127 | 1.137 | 0.964–1.340 |
| Female | 0.308 | 0.296 | 0.568 | 1.059 | 0.870–1.289 | |
| Male | 0.290 | 0.248 | 0.183 | 1.237 | 0.905–1.691 | |
| Meta-analysis: German, French, Danish | Total | 0.329 | 0.295 | 2.38E−05 | 1.188 | 1.097–1.287 |
| Female | 0.327 | 0.300 | 0.003 | 1.154 | 1.050–1.267 | |
| Male | 0.336 | 0.285 | 0.001 | 1.305 | 1.110–1.535 | |
|
| ||||||
| French | Total | 0.326 | 0.294 | 0.008 | 1.160 | 1.040–1.295 |
| Female | 0.317 | 0.291 | 0.064 | 1.131 | 0.993–1.289 | |
| Male | 0.364 | 0.298 | 0.008 | 1.345 | 1.079–1.677 | |
| Danish | Total | 0.305 | 0.262 | 0.012 | 1.235 | 1.047–1.458 |
| Female | 0.302 | 0.282 | 0.328 | 1.104 | 0.905–1.346 | |
| Male | 0.315 | 0.232 | 0.008 | 1.527 | 1.118–2.085 | |
| Meta-analysis: German, French, Danish | Total | 0.325 | 0.285 | 1.31E−06 | 1.219 | 1.125–1.321 |
| Female | 0.319 | 0.289 | 0.002 | 1.164 | 1.059–1.280 | |
| Male | 0.348 | 0.278 | 1.49E−05 | 1.426 | 1.215–1.675 | |
Listed are allele frequencies, allelic P values, odds ratios, and the 95% confidence intervals for the whole study populations (1264 LLI ≥ 91 years and 1830 younger controls (35–62 years) from France and 643 LLI ≥ 92 years and 746 younger controls (56–71 years) from Denmark) as well as for the subgroups of females (1032 LLI and 1,105 younger controls from France and 493 LLI and 456 younger controls from Denmark) and males (232 LLI and 725 younger controls from France and 150 LLI and 290 younger controls from Denmark)
a Minor allele frequency, MAF; the definition of the minor allele is based on controls; minor alleles are A for rs4946935 and T for rs12206094
b Allelic P values, PCCA; calculated with chi-squared test with one degree of freedom
c Odds ratio for longevity, OR; based on the minor allele in controls
d 95% confidence interval, 95% C.I.; C.I. for the odds ratio
Fig. 2SRF binds to the longevity allele A but not to the major allele G of rs4946935. Nuclear extracts from Panc1 a and Jurkat b cells were submitted to EMSA with the indicated oligonucleotides. Supershift experiments were performed with antibodies as listed. The position of the supershifted complex is indicated by an arrow. One biological replicate of four is shown. Gt goat, IgG immunoglobulin G, NC nonspecific control (NC I: anti-STAT5A, rabbit; NC II: anti-PDX1, rabbit; NC III, anti-PDX1, goat); PDX1 pancreatic and duodenal homeobox 1, rb rabbit, SRF serum response factor
Fig. 3FOXO3 SNVs rs12206094 and rs4946935 influence luciferase promoter activity, and knockdown of SRF links this transcription factor to rs4946935. a, b Luciferase promoter assays were perfomed in Panc1 cells transfected with allele-specific constructs for rs12206094 (a) and rs4946935 (b) in both the presence and absence of FCS. For both SNVs, the promoter activity in cells transfected with constructs containing the respective major allele was set = 1 (black dot). Each white dot represents one independent experiment (n = 5). The tables below the figures show the median as well as the minimum and maximum values for the ratio of the longevity allele to the respective alternative allele, taking into account all experiments. c, d Knockdown of transcription factors was done using specific siRNAs. The luciferase activity in cells treated with control siRNA (con siRNA) instead of the transcription factorspecific siRNA was set = 1 (black dot) for each allele of each SNV. Each white dot represents one independent experiment (n = 5). The tables below the figures show the median as well as the minimum and maximum values for the ratios of the activity in presence of con siRNA and transcription factor-specific siRNA for each allele, taking into account all experiments. a–d For determination of specific luciferase activity, activity of the firefly luciferase was normalized to the activity of the renilla luciferase. P ≤ 0.05 was considered statistically significant (two-sided Wilcoxon signed-rank test for paired data). A.U., arbitrary luminescence units
Fig. 4IGF-1 treatment reduces luciferase promoter activity in the presence of the longevity alleles of rs12206094 and rs4946935, respectively. a, b Luciferase promoter assays were perfomed in Panc1 cells transfected with allele-specific constructs for rs12206094 (a) and rs4946935 (b). The activity of cells treated with DMSO as control instead of IGF-1 was set = 1 (black dot) for each allele of each SNV. Each white dot represents one independent experiment (n = 6). Final DMSO concentrations did not exceed 0.1%. The tables below the figures show the median as well as the minimum and maximum values for the ratios of the activity in presence of DMSO and 100 ng/mL IGF-1 for each allele, taking into account all experiments. For determination of specific luciferase activity, activity of the firefly luciferase was normalized to the activity of the renilla luciferase. P ≤ 0.05 was considered statistically significant (two-sided Wilcoxon signed-rank test for paired data). A.U., arbitrary luminescence units